Sign Out
Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.
There is inadequate evidence of safety of BECONASE in human pregnancy. In animal reproduction studies adverse effects typical of potent corticosteroids are only seen at high systemic exposure levels; direct intranasal application ensures minimal systemic exposure.
The excretion of beclometasone dipropionate in milk has not been studied in animals. It is reasonable to assume that beclometasone dipropionate is secreted in milk but at the dosage used for the intranasal application, there is low potential for significant levels in breast milk. BECONASE should only be used in a nursing mother if the expected benefit justifies the risk to the infant.
